Promising new combo aims to extend life in rare, Tough-to-Treat cancer
NCT ID NCT07337447
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding two immunotherapy drugs (zimberelimab and domvanalimab) to standard chemotherapy (FOLFIRI) helps people with a rare, fast-growing neuroendocrine cancer live longer. About 122 adults whose cancer has worsened after first treatment will take part. The goal is to see if the combination improves survival at 12 months compared to chemotherapy alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NEUROENDOCRINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Amiens Picardie
Amiens, France
-
CHU Avicenne APHP
Bobigny, France
-
CHU Caen Normandie
Caen, France
-
CHU Dijon
Dijon, France
-
CHU Montpellier - Hôpital Saint Eloi
Montpellier, France
-
CHU Rouen
Rouen, France
-
CHU Timone
Marseille, France
-
CHU de Bordeaux - Hôpital Haut-Leveque
Pessac, France
-
CHU de Grenoble
Grenoble, France
-
CHU de Poitiers
Poitiers, France
-
Centre Oscar Lambret
Lille, France
-
Centre Paul Strauss
Strasbourg, France
-
HEGP
Paris, France
-
Hôpital Beaujon
Clichy, France
-
Hôpital Henri MONDOR
Créteil, France
-
Hôpital Robert Debré, CHU de Reims
Reims, France
-
Hôpital Saint Antoine APHP
Paris, France
-
Hôpital Saint Louis APHP
Paris, France
-
Institut Gustave Roussy
Villejuif, France
-
Institut Paoli Calmettes
Marseille, France
-
Service d'Oncologie Médicale - Hôpital Edouard Herriot - Hospices Civils de Lyon
Lyon, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.